TABLE 2.

Overview of Tac doses and target concentration achievement

	Computer Group		Control Group
	Number / Median [95% CI]	Range	Number / Median [95% CI]	Range	p-value
Standard risk (3-7 μg/L)
Patients	32		35
Tac concentrations	605		844
Tac concentrations per patient	24	8-30	24	12-40
Tac initial dose (mg/day)	5.0	4.0-8.0	5.5	4.0-8.0	0.96
Tac dose at discharge (mg/day)	4.0	1.0-9.0	4.0	2.0-13.0	0.04
Mean Tac dose during follow-up (mg/day)	4.1	1.3-9.8	4.8	2.1-11.4	0.13
Tac dose, intra-subject variability (CV%)	29%		24%		0.14
Tac trough concentration (μg/L)	5.1	1.8-11.3	5.8	1.0-13.6	<0.001
Mean Tac trough concentration during follow up (μg/L)	5.1	4.6-6.5	5.9	4.8-7.1	<0.001
Tac trough concentration, intra- subject variability (CV%)	23%		26%		0.16
Concentrations within target range per patient	90% [84-95%]	67-100%	78% [76-82%]	58-96%	<0.001
Below target range	0% [0-0%]	0-11%	0% [0-2%]	0-18%	0.80
Above target range	9% [2-11%]	0-33%	18% [15-23%]	4-42%	<0.001
Time to achieve target concentration (days)	2	2-5	3	2-8	0.29
High-risk (8-12 μg/L day 1-30, 6-10 μg/L day 31+)
Patients	7		4
Tac concentrations	141		121
Tac concentrations per patient	22	21-25	28	20-31
Tac initial dose (mg/day)	7.0	5.0-10.0	6.0	5.0-6.0	0.35
Tac dose at discharge (mg/day)	6.0	2.0-9.0	6.0	5.0-9.0	1.00
Mean Tac dose during follow-up (mg/day)	7.8	3.6-11.5	7.4	7.7-11.3	0.92
Tac dose, intra-subject variability (CV%)	24%		22%
Tac trough concentration (μg/L)	9.7	5.3-16.9	9.6	1.9-16.5	0.46
Mean Tac trough concentration during follow up (μg/L)	9.8	8.9-10.9	9.7	7.5-10.8	0.78
Tac trough concentration, intra- subject variability (CV%)	22%		31%
Concentrations within target range per patient	77% [71-80%]	61-84%	59% [40-74%]	40 -74%	0.04
Below target range	16% [10-17%]	0-24%	31% [11-32%]	11-32%	0.11
Above target range	10% [5-22%]	0-23%	12% [7-30%]	7-30%	0.53
Time to achieve target concentration (days)	3	2-7	4.5	4-10	0.04

CI, confidence interval; CV, coefficient of variation; Tac, tacrolimus

p-values were calculated using the Mann-Whitney U test